MA27772A1 - Preparation pharmaceutique orale destinee aux antagonistes de la pompe a protons - Google Patents

Preparation pharmaceutique orale destinee aux antagonistes de la pompe a protons

Info

Publication number
MA27772A1
MA27772A1 MA28575A MA28575A MA27772A1 MA 27772 A1 MA27772 A1 MA 27772A1 MA 28575 A MA28575 A MA 28575A MA 28575 A MA28575 A MA 28575A MA 27772 A1 MA27772 A1 MA 27772A1
Authority
MA
Morocco
Prior art keywords
antagonists
proton pump
pharmaceutical preparation
oral pharmaceutical
proton
Prior art date
Application number
MA28575A
Other languages
English (en)
Inventor
Rango Dietrich
Bernd-Michael Hass
Hartmut Ney
Simone Hiltl
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33160619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27772(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10317023A external-priority patent/DE10317023A1/de
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of MA27772A1 publication Critical patent/MA27772A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouvelles formes posologiques destinées aux antagonistes de la pompe à protons.
MA28575A 2003-04-11 2005-11-02 Preparation pharmaceutique orale destinee aux antagonistes de la pompe a protons MA27772A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03008453 2003-04-11
DE10317023A DE10317023A1 (de) 2003-04-11 2003-04-11 Perorale Arzneimittelzubereitung für Protonenpumpenantagonisten

Publications (1)

Publication Number Publication Date
MA27772A1 true MA27772A1 (fr) 2006-02-01

Family

ID=33160619

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28575A MA27772A1 (fr) 2003-04-11 2005-11-02 Preparation pharmaceutique orale destinee aux antagonistes de la pompe a protons

Country Status (19)

Country Link
US (1) US20060204568A1 (fr)
EP (1) EP1615624A2 (fr)
JP (1) JP2006522776A (fr)
KR (1) KR20060002932A (fr)
AR (1) AR044004A1 (fr)
AU (1) AU2004228961A1 (fr)
BR (1) BRPI0409175A (fr)
CA (1) CA2526869A1 (fr)
CL (1) CL2004000767A1 (fr)
EA (1) EA200501565A1 (fr)
IS (1) IS8107A (fr)
MA (1) MA27772A1 (fr)
MX (1) MXPA05010705A (fr)
NO (1) NO20055207L (fr)
PE (1) PE20050414A1 (fr)
RS (1) RS20050756A (fr)
TN (1) TNSN05233A1 (fr)
TW (1) TW200503783A (fr)
WO (1) WO2004089342A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
AU2005291302A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2009048993A2 (fr) 2007-10-12 2009-04-16 Novartis Ag Compositions comprenant des modulateurs du récepteur de sphingosine 1-phosphate (s1p)
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CN104784180A (zh) 2008-07-28 2015-07-22 武田药品工业株式会社 药物组合物
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JP6778680B2 (ja) 2015-07-30 2020-11-04 武田薬品工業株式会社 錠剤
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464372A (en) * 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
GB8422461D0 (en) * 1984-09-05 1984-10-10 Wyeth John & Brother Ltd Pyridine derivatives
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4833149A (en) * 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
US5362743A (en) * 1993-03-09 1994-11-08 Pfizer Inc. Aminoquinoline derivatives
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
BR9807883A (pt) * 1997-03-24 2000-02-22 Byk Gulden Lomberg Chem Fab Compostos de tetraidropirido
WO1998050019A1 (fr) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Formes posologiques pharmaceutiques orales stables
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
WO2000017200A1 (fr) * 1998-09-23 2000-03-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydropyridoethers
EE200100660A (et) * 1999-06-07 2003-04-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
AU782538B2 (en) * 1999-10-20 2005-08-04 Eisai Co. Ltd. Method for stabilizing benzimidazole compounds
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same

Also Published As

Publication number Publication date
NO20055207L (no) 2005-11-04
TNSN05233A1 (en) 2007-06-11
PE20050414A1 (es) 2005-06-18
EA200501565A1 (ru) 2006-06-30
AU2004228961A1 (en) 2004-10-21
AR044004A1 (es) 2005-08-24
BRPI0409175A (pt) 2006-04-11
IS8107A (is) 2005-10-31
CA2526869A1 (fr) 2004-10-21
RS20050756A (sr) 2007-11-15
KR20060002932A (ko) 2006-01-09
JP2006522776A (ja) 2006-10-05
US20060204568A1 (en) 2006-09-14
WO2004089342A3 (fr) 2005-03-10
EP1615624A2 (fr) 2006-01-18
CL2004000767A1 (es) 2005-05-27
WO2004089342A2 (fr) 2004-10-21
MXPA05010705A (es) 2005-12-12
TW200503783A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
BR0210078A (pt) Composto, uso do mesmo, e, formulação farmacêutica
ATE356119T1 (de) Pyrimidinone als melanin concentrating hormone receptor 1
PT1506185E (pt) Compostos novos e sua utilizacao
BRPI0414539A (pt) composto, composição farmacêutica, e, uso de um composto
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
MXPA05009985A (es) Ligandos de receptores de canabinoides.
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
UY28348A1 (es) Compuestos novedosos
MY140987A (en) Specific glucocorticosteroid compound having anti-inflammatory activity
EA199900373A2 (ru) Фармацевтические композиции
BR0215042A (pt) fenil-naftalenos substituìdos como agentes estrogênicos
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
EP0738152A4 (fr) Agents de chimioprevention ou de chimiotherapie du cancer du colon a base de derives de l'acide 2-hydroxy-5-phenylazobenzoique
EA200300937A1 (ru) Оральная фармацевтическая композиция цефподоксима проксетила
CO5590918A2 (es) Formulaciones
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
DE60302157D1 (de) Opioidrezeptorantagonisten
SE9804212D0 (sv) Compounds
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
DE602004016752D1 (de) Kombination enthaltend substanzen mit npy-rezeptor affinität und substanzen mit 5-ht6-rezeptor affinität